LARIMAR THERAPEUTICS LRMR 深 沪
等待开盘 11-07 09:30:00 美东时间
3.47
+0.250
+7.76%
华盛通- 最 高3.565
- 今 开3.19
- 成交量 233.34万股
- 最 低 3.18
- 昨 收 3.22
- 总市值 2.97亿
- 52周最高 6.91
- 市盈率 静 --
- 换手率 2.73%
- 52周最低 1.61
- 委 比 16.89%
- 总股本 8559.04万
- 历史最高 664.32
- 量 比 1.26
- 振 幅 11.96%
- 历史最低 1.53
- 每 手 1
- 风险率 1.42%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Larimar Therapeutics Q3 EPS $(0.61) Misses $(0.40) Estimate
Larimar Therapeutics (NASDAQ:LRMR) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.40) by 51.36 percent. This is a 154.17 percent decrease over losses of $(0.24) per
11-05 20:09
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining aroun...
10-06 20:09
美股大行评级 | 潜在涨幅216.96%！Kazia Therapeutics获Maxim Group升目标价至20美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Kazia Therapeutics"买入"评级，目标价从15美元升至20美元；Baird：维持Taysha Gene Therapies"跑赢大市"评级，目标价从7美元升至12美元
10-03 14:32
美股牛股 | AI基础设施REIT公司Fermi上市首日收涨54.9%；DXYZ大涨超30%
AI基础设施REIT公司Fermi登陆美股首日收涨54.9%，市值近200亿美元；DXYZ大涨超30%
10-02 16:55
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
Larimar Therapeutics Analyst Ratings
Unity Software(U.US) reported fourth-quarter financial results after the market...
09-30 19:40
快讯 | 拉里玛治疗公司：琼斯交易将目标价从10美元下调至7美元
Larimar Therapeutics Inc : Jonestrading Cuts Target Price to $7 From $10
09-30 11:45
Market-Moving News for September 29th
LRMR: -53% | Larimar shares are trading lower after the company reported seven patients experienced anaphylaxis and were withdrawn from its long-term study evaluating daily subcutaneous injections of
09-29 19:20
Why Merus Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
09-29 17:07
Larimar Therapeutics Announces Positive Data from Ongoing Long-term Open Label Study and Updates to Nomlabofusp Program for Friedreich’s Ataxia
Larimar Therapeutics announced positive results from its ongoing long-term open-label study of nomlabofusp for Friedreich’s ataxia (FA). The study showed consistent improvement in four key clinical outcomes and increased skin FXN levels to over 50% of healthy volunteer levels after six months of treatment. While anaphylaxis was reported in 7 participants, long-term dosing was generally well-tolerated. Larimar modified its dose regimen to enhance ...
09-29 11:00
